Global PTCA Coronary Drug Eluting Balloons Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global PTCA Coronary Drug Eluting Balloons market size was valued at US$ 730 million in 2025 and is forecast to a readjusted size of US$ 1759 million by 2032 with a CAGR of 13.2% during review period.
PTCA coronary drug-eluting balloons—commonly referred to as coronary drug-coated/drug-eluting balloons (coronary DCB/DEB)—are angioplasty balloons used in percutaneous transluminal coronary angioplasty (PTCA) with an antiproliferative drug (predominantly paclitaxel, with growing “limus” exploration) plus an excipient/carrier layer on the balloon surface. During inflation, they provide immediate lumen gain while rapidly transferring drug into the vessel wall to suppress neointimal hyperplasia and reduce restenosis and repeat interventions. The strategic proposition is “leave nothing behind,” aiming to avoid additional permanent metal/polymer layers and preserve future treatment flexibility—most compelling in coronary in-stent restenosis (ISR), small-vessel disease, and selected bifurcation strategies. In 2025, global PTCA coronary drug-eluting balloons production reached approximately 755 k units and price is 940 USD/Unit.The average gross profit margin of this product is 73%.
A clear commercialization inflection has emerged: in March 2024, the U.S. FDA approved the first coronary drug-coated balloon for ISR (the AGENT DCB), significantly increasing global visibility and strengthening hospital adoption confidence. Concurrent randomized evidence and high-impact editorial perspectives reinforced the evidence base for ISR, accelerating the shift from experience-driven use to pathway-manageable standard practice. Over a longer horizon, coronary intervention is evolving from implant-centric approaches toward repair strategies that prioritize controllable reintervention, where DCBs benefit from a value narrative centered on reducing multilayer implants and long-term implant burden.
The key constraints are indication boundaries and reproducibility. Beyond ISR—where evidence is strongest—recent data in previously untreated, non-complex coronary disease did not support DCB as a straightforward substitute for second-generation DES as the preferred strategy, underscoring the need for tighter lesion selection, procedural standardization, and follow-up evidence as the market expands. Coronary anatomy also imposes higher demands on deliverability, coating integrity, and drug-transfer performance; batch variability can translate into outsized clinical experience and access risk. Combined with regional differences in combination-product regulation and hospital value assessment, manufacturers must build durable, repeatable capabilities across evidence, quality systems, and supply assurance.
Demand is shifting from single devices toward repeatable coronary repair solutions. Clinical practice increasingly emphasizes lesion preparation (adequate pre-dilation, managing calcium and dissection risk), intraprocedural assessment, and avoiding additional stent layers—clarifying DCB’s role in ISR, small vessels, and selected bifurcation strategies, often in combination with specialty balloons, plaque modification, and imaging guidance. With the U.S. entering a compliant “coronary DCB era,” ecosystem build-out around indication education, technique standardization, and real-world follow-up is accelerating, enabling hospitals to incorporate DCB into managed pathways and bundled device sets with greater predictability and scaling potential.
Upstream differentiation is ultimately a platform capability spanning materials, coating, and validation. Key inputs include balloon films and catheter polymers (multi-durometer shafts, liners, reinforcement braids/coils), drug APIs (paclitaxel or limus agents) with crystallinity/particle control, excipient and solvent systems, lubricious/hydrophilic surface coatings, plus sterile barrier packaging and sterilization services. Because coronary use is highly sensitive to particulate control, coating integrity, dose consistency, deliverability, and stability, the supply chain must operate with medical-grade traceability, clean manufacturing, robust change control, and strict release standards to industrialize “drug transfer + delivery performance + long-term stability” as a repeatable engineering capability.
This report is a detailed and comprehensive analysis for global PTCA Coronary Drug Eluting Balloons market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PTCA Coronary Drug Eluting Balloons market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PTCA Coronary Drug Eluting Balloons market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PTCA Coronary Drug Eluting Balloons market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PTCA Coronary Drug Eluting Balloons market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PTCA Coronary Drug Eluting Balloons
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PTCA Coronary Drug Eluting Balloons market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include B. Braun, Eurocor, Teleflex, Yinyi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PTCA Coronary Drug Eluting Balloons market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Paclitaxel-based
limus
Other
Market segment by Use Scenario
In-Stent Restenosi
De novo
Small Vessel
Market segment by Balloon Platform Mechanics
Semi-/Compliant
Non-compliant
Other
Market segment by Application
Cardiac Catheterization Lab
Hospital
Other
Major players covered
B. Braun
Eurocor
Teleflex
Yinyi
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PTCA Coronary Drug Eluting Balloons product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PTCA Coronary Drug Eluting Balloons, with price, sales quantity, revenue, and global market share of PTCA Coronary Drug Eluting Balloons from 2021 to 2026.
Chapter 3, the PTCA Coronary Drug Eluting Balloons competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PTCA Coronary Drug Eluting Balloons breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and PTCA Coronary Drug Eluting Balloons market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PTCA Coronary Drug Eluting Balloons.
Chapter 14 and 15, to describe PTCA Coronary Drug Eluting Balloons sales channel, distributors, customers, research findings and conclusion.